FNIH Launches Landmark MAP-D Study to Redefine Depression Diagnosis and Treatment Through Precision Medicine
Key Insights
The FNIH announced the launch of MAP-D, a long-term study aiming to identify biomarkers for depression and define biologically distinct subtypes, moving beyond symptom-based diagnosis.
The initiative targets over $70 million in total funding, beginning with a $22 million, three-year pilot phase that will enroll more than 300 patients nationwide.
MAP-D will integrate genomics, neuroimaging, digital assessments, and patient-reported outcomes, using custom AI models to link biomarkers to patient outcomes over time.
The Foundation for the National Institutes of Health (FNIH) (search) today announced the launch of the first phase of the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative, a landmark study designed to transform how major depressive disorder (search) is defined, diagnosed, and treated. The initiative, which ultimately aims to commit more than $70 million to the effort, is currently focused on a $22 million, three-year pilot phase that will enroll more than 300 patients nationwide.
The study brings together a broad coalition of partners representing academia, patient advocacy groups, philanthropists, and life sciences companies, with the National Institute of Mental Health and the Food and Drug Administration serving in advisory roles. Alexandria Real Estate Equities, Inc. (search) served as the founding strategic partner, providing initial catalytic funding and securing cross-sector support to establish the public-private partnership.
The Unmet Need in Depression Care
Depression represents one of the defining health challenges of our time. Over 21 million U.S. adults experience a major depressive episode each year, and depression costs an estimated $380 billion annually in healthcare, lost productivity, and human suffering. Nearly one-third of those affected suffer from treatment-resistant depression (search).
"Depression is a growing public health issue and one of the defining health challenges of our time. It represents a heavy burden to society and families," said Julie Gerberding, MD, MPH, President and CEO of the FNIH. "We still lack reliable, practical tools to understand and measure this complex disease, and it will require a long-term, collaborative commitment from many organizations to deliver the right treatments and better outcomes."
Currently, treatment for major depressive disorder (search) often follows a generalized, trial-and-error approach, with the majority of patients failing to respond to initial treatments. The challenge is compounded by the fact that most antidepressants require weeks or months to achieve effective symptomatic relief.
A Precision Medicine Framework for Depression
For years, depression has been diagnosed as a single disease based on symptoms, yet the underlying causes can vary significantly from person to person. MAP-D aims to change this paradigm by rigorously profiling individuals aged 15 and older with moderate to severe depression. Conditions that frequently occur alongside depression—such as PTSD (search) and bipolar disorder (search)—will also be studied together to better reflect real-world patient experience.
"Identifying biologically distinct subtypes of depression is one of the most important challenges facing mental health research today," said Steve Hoffmann, MS, Senior Vice President and Chief Preclinical Officer at the FNIH. "The integration of multimodal biomarkers, digital measures, imaging, biological assays and clinical assessments has the potential to transform how we differentiate patients and guide treatment selection."
The study will generate what is described as the most comprehensive, integrated dataset assembled to date, combining multi-modal biomarker data including genomics, neuroimaging, digital and clinical assessments, and real-world, patient-reported outcomes. Custom AI models will be used to link those biomarkers to patient outcomes over time.
"MAP-D is creating the evidence base and AI models needed to move from a one-size-fits-all approach toward precision-driven care that delivers the right treatment to the right patient at the right time," Hoffmann added.
Study Design and Future Scale
The insights generated through the three-year pilot will inform expansion to Phase 1b, with the potential to scale to more than 2,500 patients as the program grows and demonstrates success. The data will help validate better tools to measure and track depression and other mental health conditions for both drug development and use in clinical care.
Among its critical objectives, the public-private partnership will strive to make its data broadly accessible to qualified researchers, foster transparency, accelerate scientific discovery, and extend the benefits of its precision medicine framework to other serious mental illnesses.
Broad Coalition of Support
The initiative is supported by AbbVie (search), Alexandria Real Estate Equities, Inc. (search), Alto Neuroscience, the American Psychiatric Association Foundation, Circular Genomics, Cogstate Ltd, Definium Therapeutics, Eli Lilly and Company, Engrail Therapeutics (search), the National Alliance on Mental Illness (NAMI), and Neumarker Inc., and is funded in part through philanthropic support to the FNIH, including from Julian Abdey.
Academic researchers contributing scientific expertise include Maurizio Fava, MD (Harvard University), Leanne Williams, PhD (Stanford University), Conor Liston, MD, PhD (Cornell University), and Katherine Burdick, PhD (Columbia University).
"Major depressive disorder (search) affects more than 21 million adults in the United States each year, nearly one-third of whom suffer from treatment-resistant depression (search)," said Lynne Zydowsky, PhD, chief of science at Alexandria Real Estate Equities, Inc. (search) and Alexandria Venture Investments. "For too long, depression has been diagnosed primarily through symptoms and treated as a single disease, despite the biological differences that exist from one patient to another and the frequent overlap with related conditions such as PTSD (search). We are proud to partner with the FNIH to advance a transformative precision medicine framework that has the potential to fundamentally improve how depression is understood, diagnosed and treated."